Literature DB >> 31004295

Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group.

Alexandra G Lopez-Aguiar1, Mohammad Y Zaidi1, Eliza W Beal2, Mary Dillhoff2, John G D Cannon3, George A Poultsides3, Zaheer S Kanji4, Flavio G Rocha4, Paula Marincola Smith5, Kamran Idrees5, Megan Beems6, Clifford S Cho6, Alexander V Fisher7, Sharon M Weber7, Bradley A Krasnick8, Ryan C Fields8, Kenneth Cardona1, Shishir K Maithel9.   

Abstract

BACKGROUND: Preoperative factors that reliably predict lymph node (LN) metastases in pancreatic neuroendocrine tumors (PanNETs) are unclear. The number of LNs needed to accurately stage PanNETs has not been defined.
METHODS: Patients who underwent curative-intent resection of non-functional PanNETs at eight institutions from 2000 to 2016 were analyzed. Preoperative factors associated with LN metastases were identified. A procedure-specific target for LN retrieval to accurately stage patients was determined.
RESULTS: Of 695 patients who underwent resection, 33% of tumors were proximal (head/uncinate) and 67% were distal (neck/body/tail). Twenty-six percent of patients (n = 158) had LN-positive disease, which was associated with a worse 5-year recurrence-free survival (RFS; 60% vs. 86%; p < 0.001). The increasing number of positive LNs was not associated with worse RFS. Preoperative factors associated with positive LNs included tumor size ≥ 2 cm (odds ratio [OR] 6.6; p < 0.001), proximal location (OR 2.5; p < 0.001), moderate versus well-differentiation (OR 2.1; p = 0.006), and Ki-67 ≥ 3% (OR 3.1; p < 0.001). LN metastases were also present in tumors without these risk factors: < 2 cm (9%), distal location (19%), well-differentiated (23%), and Ki-67 < 3% (16%). Median LN retrieval was 13 for pancreatoduodenectomy (PD), but only 9 for distal pancreatectomy (DP). Given that PD routinely includes a complete regional lymphadenectomy, a minimum number of LNs to accurately stage patients was not identified. However, for DP, removal of less than seven LNs failed to discriminate 5-year RFS between LN-positive and LN-negative patients (less than seven LNs: 72% vs. 83%, p = 0.198; seven or more LNs: 67% vs. 86%; p = 0.002).
CONCLUSIONS: Tumor size ≥ 2 cm, proximal location, moderate differentiation, and Ki-67 ≥ 3% are preoperative factors that predict LN positivity in resected non-functional PanNETs. Given the 9-23% incidence of LN metastases in patients without such risk factors, routine regional lymphadenectomy should be considered. PD inherently includes sufficient LN retrieval, while DP should aim to remove seven or more LNs for accurate staging.

Entities:  

Mesh:

Year:  2019        PMID: 31004295     DOI: 10.1245/s10434-019-07367-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

Review 1.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

2.  A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique.

Authors:  Adriana C Gamboa; Yuan Liu; Rachel M Lee; Mohammad Y Zaidi; Charles A Staley; Maria C Russell; Kenneth Cardona; Patrick S Sullivan; Shishir K Maithel
Journal:  J Surg Oncol       Date:  2019-08-26       Impact factor: 3.454

Review 3.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 4.  How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.

Authors:  Francesca Fermi; Valentina Andreasi; Francesca Muffatti; Stefano Crippa; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Curr Oncol Rep       Date:  2022-01-25       Impact factor: 5.075

5.  Preoperative prediction of lymph node metastasis in nonfunctioning pancreatic neuroendocrine tumors from clinical and MRI features: a multicenter study.

Authors:  Hai-Bin Zhu; Pei Nie; Liu Jiang; Juan Hu; Xiao-Yan Zhang; Xiao-Ting Li; Ming Lu; Ying-Shi Sun
Journal:  Insights Imaging       Date:  2022-10-08

6.  Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis.

Authors:  Kota Sahara; Diamantis I Tsilimigras; Rittal Mehta; Amika Moro; Anghela Z Paredes; Alexandra G Lopez-Aguiar; Flavio Rocha; Zaheer Kanji; Sharon Weber; Alexander Fisher; Ryan Fields; Bradley A Krasnick; Kamran Idrees; Paula M Smith; George A Poultsides; Eleftherios Makris; Cliff Cho; Megan Beems; Mary Dillhoff; Shishir K Maithel; Itaru Endo; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2019-12-14       Impact factor: 5.344

7.  Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours.

Authors:  Jaseela Chiramel; Rose Almond; Astrid Slagter; Adeel Khan; Xin Wang; Kok Haw Jonathan Lim; Melissa Frizziero; Bipasha Chakrabarty; Annamaria Minicozzi; Angela Lamarca; Wasat Mansoor; Richard A Hubner; Juan William Valle; Mairéad Geraldine McNamara
Journal:  World J Clin Oncol       Date:  2020-04-24

8.  Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors.

Authors:  Zheng Zhang; Fei Wang; Zheng Li; Zeng Ye; Qifeng Zhuo; Wenyan Xu; Wensheng Liu; Mengqi Liu; Guixiong Fan; Yi Qin; Yue Zhang; Xuemin Chen; Xianjun Yu; Xiaowu Xu; Shunrong Ji
Journal:  BMC Surg       Date:  2022-05-10       Impact factor: 2.102

9.  Prognostic Factors of Small Non-Functional Pancreatic Neuroendocrine Tumors and the Risk of Lymph Node Metastasis: A Population-Level Study.

Authors:  Qingquan Tan; Xing Wang; Yichen Li; Yingyi Liu; Xubao Liu; Nengwen Ke
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-06       Impact factor: 6.055

Review 10.  Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors.

Authors:  Ugo Marchese; Martin Gaillard; Anna Pellat; Stylianos Tzedakis; Einas Abou Ali; Anthony Dohan; Maxime Barat; Philippe Soyer; David Fuks; Romain Coriat
Journal:  Cancers (Basel)       Date:  2022-01-15       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.